BMI's Executive Summary

[TOP]

The German drug market should grow at a rate of 3.19% between 2007-2012, with OTC drugs and the expansion of the generic sector being the main drivers of growth. Consumer health products should reach a value of US$8.5bn by 2012, due to increasing competition and the emergence of the internet as a major sales channel.

The European Commission (EC) is currently challenging restrictive pharmacy ownership laws in a number of countries, with companies like Germany's Schlecker keenly awaiting the outcome. The retailer, which sells non-medicinal consumer health products in Germany, has recently opened an online pharmacy in the Netherlands, offering over 600 OTC products. Presently, Germany only allows selfemployed pharmacists to run pharmacies, preventing chains from entering the market. However, Schlecker is looking to circumvent this by running a mail order operation through its Dutch store.

Elsewhere, plans to create a new drug approvals body in Germany have collapsed after the coalition parties in the government failed to agree on a framework for the agency, exemplifying how political infighting can de-rail reform initiatives. The new institution, provisionally called DAMA, would have replaced the current Federal Institute for Drugs and Medical Devices (BfArM), increasing the efficiency of the approvals process, which is beset by delays.

Meanwhile, Germany takes 2nd place in BMI's revised Business Environment Rankings for the Western European region. We have completely overhauled the methodology giving greater weight to regulatory factors affecting the drug market, while utilising a more nuanced analysis of country-specific economic and political factors. Germany's position derives mainly from its strong country indicators with impressive scores in areas such as policy continuity and lack of corruption. The ratings also favour larger markets, which gives Germany a further advantage, due to its high per-capita expenditure on pharmaceuticals. However, sluggish growth is having a negative impact and BMI does not envisage Germany closing the gap on regional leader Switzerland over the forecast period.

Contents

[TOP]

Chapter 1 - Executive Summary

Germany Pharmaceuticals & Healthcare Industry SWOT

Germany Political SWOT

Germany Economic SWOT

Chapter 2 - Germany: Business Environment Ranking

Table: Western Europe Business Environment Rankings

Economics - Long Term risk

Politics - Long Term risk

Regulatory Barriers

Domestic Sector Threat

Market Growth Potential

Market Size Ranking

Chapter 3 - Germany: Market Summary

Chapter 4 - Regulatory Regime

Intellectual Property Developments

Pricing & Reimbursement Issues

Retail Industry

Chapter 5 - Industry Developments

Healthcare Sector

Pharmaceutical Sector

Domestic Industry

Krankenkassen

Foreign Industry

R&D Sector

Generics Sector

Wholesaler Sector

Offshoring Sector

Epidemiology

Biotech Sector

Chapter 6 - Industry Forecast Scenario

Overall Market Forecast

Table: German Drug Market Expenditure Forecasts 2005-2010

Key Growth Factors - Industry

Table: German Health Expenditure Forecast Indicators 2004-2010

Key Growth Factors - Macroeconomic

Table: Germany - Macroeconomic Forecasts

Prescription Market Forecast

Table: Germany Prescription Drugs Market Forecast Indicators

OTC Market Forecast

Table: German OTC Market Forecast Indicators 2005-2010

Generics and Branded Market Forecasts

Table: German Generics and Branded Market Forecast Indicators 2005-2010

Export/Import Forecasts

Table: German Pharmaceuticals Exports & Imports Forecasts 2005-2010

Key Risks to BMI's Forecast Scenario

Chapter 7 - Country Snapshot: Germany Demographic Data

Section 1: Population:

Table: Demographic Indicators (2005)

Table: Rural/Urban Breakdown

Section 2: Education & Healthcare

Table: Education

Table: Healthcare: Vital Statistics

Table: Healthcare: Expenditure

Section 3: Labour Market And Spending Power

Table: Employment Indicators

Table: Consumption and Stratification

Table: Wages per year

Chapter 8 - Competitive Landscape54

Overview

Chapter 9 - Company Profiles

GlaxoSmithKline

Pfizer

Novartis

Sanofi-Aventis

Merck & Co

Bayer

Boehringer Ingelheim

Chapter 10 - BMI Forecast Modelling

How we generate our industry forecasts

Technical Process

Pharmaceutical Industry

Chapter 11 - Sources

Competitive Landscape for Europe Pharmaceuticals and Healthcare: Sample of Companies Ranked

[TOP]

Cross-border analysis of regulatory systems comparing the patenting environment, summarising regional pricing and reimbursement factors and monitoring the growth of the Pharmaceuticals sector across the region. Company SWOTs cover leading multinational and national drug companies operating in each market.

Network of European Pharmaceutical & Healthcare Sources

[TOP]

BMI's Pharmaceuticals & Healthcare Reports are based on an extensive network of multilateral organisations, government departments, pharmaceutical & healthcare industry associations, chambers of commerce and company reports. Information sources include: